Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11026647rdf:typepubmed:Citationlld:pubmed
pubmed-article:11026647lifeskim:mentionsumls-concept:C0001645lld:lifeskim
pubmed-article:11026647lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:11026647lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:11026647pubmed:issue4lld:pubmed
pubmed-article:11026647pubmed:dateCreated2001-2-20lld:pubmed
pubmed-article:11026647pubmed:abstractTextThe human heart contains at least four distinct beta-adrenoceptor subtypes, three of which have been cloned. However, the binding properties of beta-blockers to the different beta-adrenoceptor subpopulations are not yet thoroughly characterized. Human beta1-, beta2- and beta3-adrenoceptors were expressed in COS-7 cells and [125I]iodocyanopindolol saturation binding, and competition experiments with commonly used beta-blockers were performed in the respective membrane preparations. Atenolol and metoprolol were about fivefold selective for beta1- versus beta2- and beta3-adrenoceptors. Bisoprolol was approximately 15-fold selective for beta1- versus beta2- and approximately 31-fold selective for beta1- versus beta3-adrenoceptors. Carvedilol was nonselective for any beta-adrenoceptor subtype. We conclude that the beta1-selectivities of atenolol, metoprolol, and bisoprolol are lower in COS cell membranes compared with previous investigations performed in native membranes. All beta-blockers investigated bind to beta3-adrenoceptors. Differential binding properties to beta3-adrenoceptors might imply different responses as to body weight, cardiac contractility, heart rate, and growth regulation. This might imply differential indications for the drugs investigated.lld:pubmed
pubmed-article:11026647pubmed:languageenglld:pubmed
pubmed-article:11026647pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:citationSubsetIMlld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11026647pubmed:statusMEDLINElld:pubmed
pubmed-article:11026647pubmed:monthOctlld:pubmed
pubmed-article:11026647pubmed:issn0160-2446lld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:BöhmMMlld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:SchnabelPPlld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:MietGGlld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:ScheerAAlld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:MaackCClld:pubmed
pubmed-article:11026647pubmed:authorpubmed-author:TyrollerSSlld:pubmed
pubmed-article:11026647pubmed:issnTypePrintlld:pubmed
pubmed-article:11026647pubmed:volume36lld:pubmed
pubmed-article:11026647pubmed:ownerNLMlld:pubmed
pubmed-article:11026647pubmed:authorsCompleteYlld:pubmed
pubmed-article:11026647pubmed:pagination466-71lld:pubmed
pubmed-article:11026647pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:meshHeadingpubmed-meshheading:11026647...lld:pubmed
pubmed-article:11026647pubmed:year2000lld:pubmed
pubmed-article:11026647pubmed:articleTitleBinding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors.lld:pubmed
pubmed-article:11026647pubmed:affiliationKlinik III für Innere Medizin der Universität zu Köln, Cologne, Germany. Petra.Schnabel@uni-koeln.delld:pubmed
pubmed-article:11026647pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11026647pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:11026647pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11026647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11026647lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11026647lld:pubmed